Kestine

Selected form

Method of action: Antiallergic, Antihistamines For Systemic Use

Treatment option: Hives, Rhinitis

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kestine

Property	Description
Active ingredient	Ebastine (INN)
Form	Tablets (film-coated, fast-dissolving), Syrup
Pharmacological class	H₁-receptor antagonist (Second-generation)
General purpose	Relief of allergic symptoms
Origin	Synthetic (Piperidine derivative)

What Type of Medicine is Kestine (Ebastine)?

The medicine known commercially as Kestine contains the active ingredient Ebastine, which is classified as a second-generation H1-receptor antagonist and functions as a selective anti-allergic agent. This synthetic single-ingredient product is administered via the oral (systemic) route. Ebastine's chemical structure as a piperidine derivative is key to its high selectivity for peripheral H1 receptors. This distinction means the medicine is clinically recognized for targeting allergy symptoms while limiting activity in the central nervous system, a key differentiating factor from older antihistamines.

Composition and Action: Understanding Ebastine as a Prodrug

Ebastine is classified as a prodrug—an inactive compound that the body must convert into a therapeutic agent. It is rapidly metabolized into its principal active compound, Carebastine, after administration in forms such as tablets and syrup. This metabolic conversion ensures the drug's sustained efficacy and long-acting profile. Consequently, the medication provides dependable, prolonged relief from allergy symptoms throughout the day. The availability of fast-dissolving tablets (FDT) is a specific formulation feature of Kestine designed for quick and convenient administration, especially useful for patients with difficulty swallowing standard film-coated tablets.

General Purpose: What Does Kestine Help Relieve?

The fundamental purpose of this anti-allergic agent is to provide relief of symptoms associated with allergic conditions by performing selective peripheral antagonism of histamine. The action of the active metabolite, Carebastine, prevents the activation of H1 receptors, thereby preventing the full manifestation of the allergic reaction. The use of Kestine is typically focused on scenarios where a patient requires relief from the persistent sneezing, itching, and congestion characteristic of chronic allergies. Crucially, the compound exhibits very limited ability to cross the blood-brain barrier, which is why it is characterized by a non-sedating profile for most individuals, allowing for minimal interference with daily activity.

What side effects are possible with Kestine?

Possible Side Effects and Safety Information

The official safety information for Kestine (Ebastine) structures its adverse event profile using standard regulatory frequency classifications, grouping potential reactions by the affected physiological system, known as the System-Organ Class (SOC).

Adverse Reactions Classified by Frequency

Adverse reactions listed in regulatory documents are classified by their expected incidence:

Common (occurring in 1% to 10% of patients): Headache, Dry mouth, and Somnolence (Drowsiness).
Uncommon (occurring in 0.1% to 1% of patients): Reactions such as Dizziness, Insomnia, Rhinitis, Nausea, Abdominal pain, Rash, and Urticaria (hives) have been documented.
Rare (occurring in 0.01% to 0.1% of patients): Includes Hypersensitivity reactions (such as Anaphylaxis and Angioedema), Palpitations, Tachycardia (fast heart rate), and Abnormal liver function test results.

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights the potential for Hypersensitivity reactions as a serious adverse event, listed in the Rare category. Additionally, there is a documented risk of QTc interval prolongation, particularly when Kestine is used alongside medicines known to affect the heart’s electrical activity or those that inhibit the CYP3A4 enzyme.

Usage of Kestine is Contraindicated in individuals with known sensitivity to the active substance or any component, and in patients with Severe Liver Impairment. Safety and efficacy have not been established in children under 12 years of age, and specific caution is required for patients with pre-existing risk factors for QTc prolongation.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Kestine

Overdose Signs and Manifestations

Clinical studies evaluating high doses up to 100 mg once daily reported no clinically significant signs or symptoms in the subjects examined. Nonetheless, acute exposure to supratherapeutic doses may result in manifestations requiring professional medical attention. Officially documented presentations include the potential for increased Somnolence (drowsiness) and Dizziness, which can occur, particularly in sensitive individuals. Overdose exposure may also increase the systemic risk of Antimuscarinic effects.

Required Emergency Actions

Immediate medical attention must be sought if an overdose is confirmed or suspected. Government guidance mandates a specific management protocol primarily due to the potential for serious effects on the Cardiovascular System. This protocol requires:

ECG Monitoring: Continuous Electrocardiogram monitoring and expert assessment of the QTc interval are necessary procedures, with observation generally recommended for at least 24 hours.
Supportive Treatment: Treatment must be purely Symptomatic and supportive since there is no specific antidote known for Ebastine documented in the labeling.
Procedural Steps: Healthcare professionals must be prepared to initiate Gastric lavage to remove unabsorbed medicine and provide comprehensive supportive care while continuously monitoring vital functions.

Population Notes

Adverse reactions observed in the pediatric population during clinical trials were documented as similar to those observed in adults.

Therapeutic Uses of Kestine

Main Uses and Benefits of Kestine

Kestine is an antihistamine medication containing the active ingredient ebastine. It is primarily used to manage symptoms associated with allergic reactions by blocking the action of histamine, a substance in the body that causes allergic symptoms.

Allergic Rhinitis

Kestine is commonly used to treat both seasonal and perennial allergic rhinitis. It helps alleviate the respiratory and nasal symptoms that occur when the immune system overreacts to environmental allergens. Key benefits in this area include the relief of:

Nasal congestion and runny nose: Reducing the production of excess mucus.
Sneezing: Minimizing the irritation in the nasal passages.
Itchy or watery eyes: Relieving ocular symptoms often associated with hay fever.

Allergic Dermatitis and Urticaria

Beyond respiratory symptoms, Kestine is effective in managing skin-related allergic conditions, such as chronic idiopathic urticaria (hives). It helps address the discomfort associated with skin reactions by:

Reducing pruritus: Providing relief from intense itching.
Managing wheals: Decreasing the formation and appearance of raised, red welts on the skin.

Mechanism and Efficacy

As a long-acting H1-receptor antagonist, Kestine is designed to provide sustained relief from symptoms. Its primary benefit is its ability to inhibit the histamine response without significant sedative effects in most individuals, allowing for the management of chronic or acute allergy symptoms while maintaining daily activity.

Eligibility and Restrictions for Use

Eligibility for Kestine (Ebastine)

Official regulatory documents define strict criteria for the use of Kestine, primarily based on age, physiological status, and underlying medical conditions.

Eligibility Group	Regulatory Status
Age (Adults/Adolescents)	Approved for use in individuals 12 years of age and older.
Age (Children <12 years)	Safety and efficacy have not been established; use is generally restricted or not recommended.
Renal Impairment	No dose adjustment is necessary for patients with any degree of kidney impairment.
Mild/Moderate Hepatic Impairment	No dose adjustment is necessary.
Severe Hepatic Insufficiency	Contraindicated in some regions; the maximum dose must not exceed 10 mg per day where use is permitted.
Pregnancy	Preferable to avoid as a precautionary measure; use only if clearly needed.
Lactation	Preferable to avoid use or Contraindicated due to unknown excretion into human milk.

Contraindications include known hypersensitivity to ebastine or any excipients, and certain hereditary metabolic disorders (e.g., galactose intolerance or phenylketonuria, depending on the formulation). The medicine must be used with caution in patients with known cardiac risk, such as a prolonged QTc interval.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Kestine (Ebastine) is defined primarily by its metabolism, which involves the CYP3A4 enzyme system. Officially documented interactions detail how co-administered substances can modify the plasma exposure of Ebastine and its active metabolite, Carebastine.

Documented Pharmacokinetic Interactions

Co-administration with potent CYP3A4 inhibitors is documented to increase the plasma exposure of Ebastine and Carebastine. Specific medicines listed in official regulatory labeling that cause this effect include the azole antifungals Ketoconazole and Itraconazole, as well as the macrolide antibiotic Erythromycin. Conversely, potent CYP3A4 inducers, such as Rifampicin, are officially documented to lower Ebastine plasma concentrations, which may reduce the antihistaminic effect.

Interactions with Food and Alcohol

Administration of Ebastine with food results in a documented pharmacokinetic effect, causing a 1.5- to 2.0-fold increase in the plasma levels (AUC) of the active metabolite, Carebastine. At therapeutic doses, official labeling confirms that no potentiation of the effects of alcohol has been observed.

Interaction-Related Restrictions

There are no medicinal products formally listed as contraindications based purely on drug-drug interaction risk. However, the maximum recommended dose of Ebastine must not be exceeded in patients with severe hepatic impairment, as this population is at heightened risk for increased drug exposure due to metabolic factors.

Mechanism of Action

The mechanism of action is mediated by the active compound, Carebastine, which is the principal metabolite of the prodrug Ebastine. The mechanism centers on the precise, non-central modulation of the histamine system.

Selective Blockade of Peripheral H1 Receptors

Carebastine acts as an inverse agonist that binds selectively to peripheral Histamine H1 Receptors ( HRH1) located on vascular, smooth muscle, and nerve cells. By occupying and stabilizing these receptors in an inactive state, the compound prevents the natural mediator, histamine, from initiating its signaling cascade. This targeted binding modulates the initial molecular events characteristic of histamine-driven receptor activation.

Modulating the Histamine-Driven Cascade

The resulting blockade modulates the propagation of the histamine-mediated inflammatory cascade. Beyond the primary receptor action, Carebastine is thought to influence the release of other pro-inflammatory mediators from certain immune cells. This mechanistic control influences the magnitude of downstream mediator release and subsequent systemic physiological events.

Peripheral Specificity and Physiological Consequences

The mechanism is defined by the restricted ability of Carebastine to penetrate the Blood-Brain Barrier (BBB). This peripheral specificity dictates that the mechanism primarily affects tissues outside the Central Nervous System (CNS) . The main physiological consequences include a reduction in histamine-induced vascular permeability, a dampening of vasodilation, and a modulation of smooth muscle tone. The action contributes to the maintenance of central H1 receptor function**, while modulating peripheral physiological responses.

Dosage and Administration Information

How Kestine (Ebastine) is Used

The administration of Kestine is governed by specific official instructions detailing the proper route, dosage, and frequency.

Official Administration and Dosing

Kestine is intended for oral administration only. It is typically taken as a film-coated tablet or a fast-dissolving (oro-dispersible) tablet in available strengths of 10 mg or 20 mg.

The standard dosing regimen for adults and adolescents (aged 12 years and older) is 10 mg once daily (OD). For the management of more pronounced symptoms in certain conditions, the dose may be increased to a maximum of 20 mg once daily.

Contextual Use Instructions

Feature	Official Instruction
Timing with Food	May be taken with or without food.
Fast-Dissolving Form	The fast-dissolving tablet is placed on the tongue to disperse rapidly and does not require water for ingestion. It must be handled with dry hands.
Dosing Limit	The dose must not exceed 10 mg once daily for patients diagnosed with severe hepatic insufficiency (severe liver impairment).
Use in Elderly/Renal	No dose adjustment is required for elderly patients or those with impaired kidney function.

This medication is characterized by a once-daily schedule which supports a prolonged use pattern as determined by the duration of symptoms. Official instructions define a standardized, simple oral administration protocol, while providing specific restrictions for use in patients with compromised liver function.

Recent Clinical Evidence

Research evidence / Overview of studies for Kestine (Ebastine)

Evidence for Use in Seasonal and Perennial Allergic Rhinitis

Research examining Kestine, which was evaluated for use in allergic rhinitis—a condition characterized by fluctuating or episodic manifestations like sneezing, runny nose, and itchy eyes—is founded upon Randomized Controlled Trials (RCTs). These studies compare Kestine to a placebo or sometimes another comparable allergy medication. Research explored the use of Kestine in adults and adolescents (typically ge 12 years) with either seasonal (SAR) or perennial (PAR) allergies.

The trials were applied in studies examining patient-reported experiences by monitoring outcomes related to physical discomfort. Researchers focused on how a collection of symptoms, known as the Total Symptom Score (TSS), changed over defined time intervals. These short-term (weeks) to intermediate-term (up to 12 weeks) studies reported how symptoms evolved in the observed populations. Studies monitored patterns observed regarding measured changes in the severity of individual symptoms.

Evidence for Use in Chronic Idiopathic Urticaria (Hives)

For Chronic Idiopathic Urticaria (CIU), a condition marked by significant skin itching (pruritus) and the appearance of wheals (hives), Kestine was also evaluated in multiple Randomized Controlled Trials. These studies involved adults with CIU, applied in research contexts involving fluctuating or unstable symptoms. A primary focus of the research examined was to track changes in outcomes related to physical discomfort.

Research documents changes measured during the study period for the overall Urticaria Activity Score (UAS), which is used to measure both the intensity of the itching and the number of visible wheals. Trials reported patterns related to these patient-reported outcomes describing perceived discomfort compared to a placebo. Despite the body of research, data are still emerging for some specific aspects.

What Research Gaps and Uncertainties Exist

Clinical and regulatory reviews acknowledge several key limitations. One is that follow-up durations were limited in many core efficacy trials, meaning that long-term effects are not fully established or well characterized. Additionally, comparative evidence is lacking in some areas, particularly concerning the use of higher doses for non-responsive patients. Research does not determine whether an individual will respond similarly, as study results reflect the specific conditions under which they were conducted.

Frequently Asked Questions (FAQ)

Common questions about Kestine (FAQ)

Q: What types of allergic dermatitis are treated with Kestine?

A: Official regulatory documents indicate that Kestine is used to relieve symptoms associated with allergic rhinitis (hay fever) and chronic idiopathic urticaria (also known as hives or nettle rash). Some international product information also lists it as an option for treating symptoms related to allergic dermatitis.

Q: Can Kestine be taken with common over-the-counter pain relievers or fever reducers?

A: Official drug labeling reports no specific drug interactions with several common medications, including Warfarin and Cimetidine. However, the product information does not provide general clearance for all over-the-counter pain relievers or fever reducers. The official documentation contains the full interaction profile.

Q: What are the official guidelines regarding the use of Kestine in patients with hereditary fructose intolerance?

A: The product’s formulation may include excipients (inactive ingredients), such as lactose, which makes it unsuitable for patients with certain hereditary metabolic disorders like galactose intolerance. Official guidelines describe that patients with hereditary sugar intolerance should review the specific excipients of their Kestine formulation.

Q: Is there a difference in efficacy between the 10 mg and 20 mg strengths of Kestine?

A: Official product information notes that the strength may be increased for the management of more pronounced or severe symptoms. Clinical data indicates that the higher 20 mg dose has been observed to demonstrate greater efficacy in controlling symptoms, particularly for chronic hives.

Q: What safety precautions are listed for Kestine use in patients with low potassium or prolonged QTc interval?

A: Official safety documentation advises caution for individuals with known risk factors that may affect the heart’s electrical activity. This includes patients with a prolonged QTc interval or those with hypokalaemia, which is the medical term for having low potassium levels in the blood.

Q: Is Kestine used for the same conditions in different countries?

A: The drug is generally indicated across different global regulatory bodies for treating allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). However, specific approvals regarding additional indications, such as allergic dermatitis, and certain age restrictions, can sometimes vary slightly from country to country.

Q: How quickly can a person expect Kestine to start providing relief from symptoms?

A: Studies reported in official clinical documentation indicate that the therapeutic anti-allergic effect of Kestine typically begins within 1 to 3 hours after a dose is taken. This time frame indicates the onset of the therapeutic effect.

Q: Is there any information about Kestine being associated with weight gain?

A: Regulatory side effect data lists weight increased as a potential adverse reaction to the drug. This reaction is reported as being very rare, based on observations from clinical trials and post-marketing surveillance.

Q: Is a change in taste (dysgeusia) a reported side effect of Kestine?

A: Yes, a side effect described as dysgeusia, which is an altered or changed sense of taste, has been reported in official product information. This particular reaction is usually classified as either rare or uncommon in the drug’s safety profile.

Q: Does Kestine affect a person's ability to drive or operate complex machinery?

A: Studies on the drug's effect on performance show no general impairment of the ability to drive or use machinery at the recommended doses. However, since side effects like somnolence (drowsiness) or dizziness can occur in certain individuals, official guidance states that those who experience these effects should exercise caution.

Q: Does Kestine interact with blood thinners like warfarin?

A: Official drug documentation and interaction studies have reported no known interaction between Kestine (Ebastine) and the blood thinner Warfarin.

Q: Is Kestine available over the counter, or is it typically prescription-only?

A: The regulatory status of Kestine varies depending on the region and local health authority approval. It is available as a prescription-only medicine in some countries, but is approved for sale over-the-counter ( OTC) for short-term allergy relief in others.

Q: Can Kestine affect the results of standard allergy skin tests?

A: Yes, official clinical guidance indicates that Kestine may interfere with the results of allergy skin tests. Regulatory documents note that the medicine is generally discontinued for a period of 5 to 7 days before testing is performed.

Q: What is known about the relationship between Kestine and potential menstrual disorders?

A: Regulatory safety information lists menstrual disorders as a potential adverse reaction to the drug. These events, including dysmenorrhoea (painful periods), are generally reported as rare or uncommon in the clinical trial data.

How should Kestine be stored and disposed of?

Storage and Disposal Requirements for Kestine (Ebastine)

The storage and disposal of Kestine tablets must strictly adhere to the conditions outlined in official regulatory documents to ensure product stability and safety.

Official Storage Conditions

Item	Requirement
Temperature Constraint	Store the medicinal product at a maximum temperature of 25 C or 30 C, depending on the formulation's regional label.
Environmental Protection	Keep in a dry place and store in the original package to protect from light.
Child Safety	Kestine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Kestine must not be disposed of via household wastewater or regular household waste. Disposal should be carried out according to local pharmaceutical waste regulations to avoid environmental contamination, as recommended by regulatory bodies.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.